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ABSTRACT
BACKGROUND: Aerosol therapy using albuterol is one of the most prescribed asthma
treatments. The most frequently used methods of aerosol delivery are pneumatic jet
nebulizer (JN), pressurized metered-dose inhaler (pMDI), and breath-actuated nebulizer
(BAN). Choosing among these devices is usually not based on thorough comparison of
efficiency or cost. We compare the efficiency of these three devices using a
spontaneously breathing adult model.
METHODS: We connected each aerosol generator—JN, BAN, or pMDI with a valved
holding chamber (VHC)—to the face of an adult teaching manikin. Below the bifurcation, an
elbow adaptor was connected to a corrugated tube and was angled to be at a lower level than
the collecting filter to prevent droplets from dripping directly into the collecting filter. From
the collecting filter, another corrugated tube was connected to a prevention filter, which was
then connected to an adult breathing simulator. Spontaneous breathing parameters were VT
450 ml, RR 20/min, and I: E ratio 1:2. First, we compared JN, BAN (2.5 mg/3 ml), and
pMDI (4 puffs); second, we compared JN and BAN 2.5 mg/0.5 ml plus 0.5 ml normal
saline. Data were analyzed using spectrophotometry (276 nm). One-way ANOVA and
independent sample t-tests were used (p<0.05).
RESULTS: There were no differences in inhaled mass percentage (p=0.172) JN, BAN,
and pMDI in the first experiment. Treatment time with BAN was significantly longer
(p=0.0001) than with JN or pMDI. In the second experiment, BAN delivered more
medication (p=0.004) than jet nebulizer. Treatment time was significantly less with JN

(p=0.010). There was no difference in residual volume among JN and BAN in both
experiment (p=0.765, p=0.115).
CONCLUSIONS: All the devices that were compared using a 3 ml or 4 pMDI puffs
delivered comparable amount of medication with no significant difference. However,
BAN using 1 ml fill volume delivers more drug compared to JN. Additionally, treatment
time was longest with BAN. Even with reduction of its filling volume, BAN delivers a
higher amount of medication to that of pMDI but was not statistically significant.
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CHAPTER I
I.

INTRODUCTION

Background and Problem
Aerosolized medications can be delivered by many means, with pneumatic jet
nebulizer (JN), pressurized metered-dose inhaler (pMDI), and breath-actuated nebulizer
(BAN) being the three most frequently used methods. Choosing among these three
devices is sometimes confusing and may not be grounded in evidence-based medicine.
Without looking at the whole picture, the selection of one device over the others could
impose significant costs that could be easily minimized by switching to a different
delivery device. The JN is considered the cheapest; however, wasted medication is
highest with this device. In fact, the deposited amount in the lung represents
approximately 15–17% of the total nebulized dose (Rau, Ari, & Restrepo, 2004). In
addition, the nebulization time using this method ranges from 9 to 11 minutes. On the
other hand, the BAN is more expensive, but since it only nebulizes during inhalation, it
can increase the deposited drug amount up to 38%. However, this device can increase the
nebulization time to be approximately 14 minutes. In contrast to these two devices, the
pMDI, especially with a valved holding chamber (VHC), are considered costly when
comparing it with the previous two devices. However, the amount of drug deposited has
been demonstrated to be comparable to that of JN (Wildhaber, Dore, Wilson, Devadason,
& LeSouef, 1999). More importantly, this method requires a shorter nebulization time,
which can decrease the labor intensity when compared with the two other devices.
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Significance
Several studies have either compared the performance of different nebulizers or
have compared certain nebulizers to pMDIs; however, no studies were found that have
compared the amount of drug deposited using the following three delivery devices: a JN,
a BAN, and a pMDI. This study fills this gap in the literature by providing a thorough
comparison of these three methods in terms of the amount of medication delivered. Such
a comparison can help to guide clinicians and decision makers in choosing the optimum
method for aerosol delivery. In addition, this study provides reliable and consistent
comparisons of three of the most widely used methods of delivering aerosol therapy.
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Purpose
The purpose of this in vitro study is to compare the amount of drug deposition,
treatment time, and residual volume that results from using pMDI-HFA with VHC, the
BAN and the JN in a spontaneously breathing adult model.
Research Questions
The following research questions provide the framework for this study:
1. What are the differences in the amounts of drug deposited in the lung between
the pMDI+VHC, JN, and BAN models?
2. What are the differences in treatment time between the pMDI +VHC, the JN,
and the BAN?
3. What are the differences in residual volume between the JN, and the BAN?
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CHAPTER II
II.

REVIEW OF LITERATURE

Pneumatic Jet Nebulizer (JN)
A small volume jet nebulizer is a small, pneumatically powered device used to
generate aerosol. It is one of the most frequently used methods to deliver medication via
inhalation route. It works by delivering a compressed gas through a jet that causes
regional negative pressure (Hess, 2000, 2008). The solution is then nebulized by being
drawn up (updraft) into a gas stream, before being sheared into smaller particles. These
particles can be further broken down by means of a baffle.
Because this device has many advantages it is quite popular. It can be used by any
age group and for any disease, and it allows nebulization of more than one drug (Geller,
2005). Moreover, patients using nebulizers have the advantage of normal tidal breathing
with no breath coordination or breath-holding required (Ari, Hess, Myers, & Rau, 2009).
On the other hand, a JN has many disadvantages including longer treatment time, the
possibility of contamination, less portability, waste of medication during exhalation, and
the need for an external source of compressed gas (Ari, et al., 2009; Geller, 2005).
Breath-Actuated Nebulizer (BAN)
BAN, also referred to as a dosimetric nebulizer, was developed to decrease the
loss of aerosolized medication during exhalation, which is a major disadvantage with the
conventional JN. This new design generates aerosol only during inspiration, which
enables the BAN to deliver more medication. An example of a BAN is the AeroEclipse®
(Monaghan Medical Corporation, Plattsburgh, NY), which is considered a mechanically
4

breath-actuated nebulizer. This nebulizer has a breath-actuated valve that can be activated
by the patient’s inspiratory effort. When a patient has entrained enough inspiratory flow
(more than 8 L/m), an actuator-piston moves down, which allows aerosol to be generated
during the inspiratory phase only. On expiration, the piston moves up to its resting
position, causing cessation of aerosol production during this phase (Leung, Louca, &
Coates, 2004).
While such a design may preserve a significant amount of medication, it requires
a longer time for nebulization because it nebulizes medication during the inspiratory
phase only. Furthermore, BAN is more expensive than the conventional JN. Since it
requires an inspiratory effort to trigger the spring-loaded valve, this device may be
appropriate only for older children and adults (Ari, et al., 2009).
Pressurized Metered Dose Inhaler (pMDI)
The pMDI is a small pressurized canister that is commonly used to administer
aerosolized medications. The pMDI has many components that play major roles in the
function of the pMDI. The components are a canister, active drugs, propellants, a
metering valve, and an actuator (S. P. Newman, 2005). Once the canister is depressed
into the actuator, it releases the propellant-drug mixture, which then expands and
vaporizes to convert the liquid medication into an aerosol. The initial vaporization of the
propellant cools the aerosol suspension. The canister aligns the hole in the metering valve
with the metering chamber when it is pressed down. Then, the high propellant vapor
pressure forces a premeasured dose of medication out of this hole and through the
actuator nozzle. Releasing the metering valve refills the chambers with another dose of
5

the drug-propellant mixture(Ari, et al., 2009).
Compared to conventional jet nebulizer, the pMDI has numerous benefits. It is a
portable, small, compact, and easy to use device. Conveniently, pMDIs can deliver
reproducible, multidoses within a significantly short period of time. Moreover, no drug
preparation is required and little contamination is likely to occur. The pMDI, however,
does have limitations. One of the major limitations is that the pMDI-delivered dose is
highly dependent on the patient understanding the technique. This technique includes
breath initiation, proper inspiratory pattern, breath-hold, and complex hand-breath
coordination. Patients with poor coordination may have trouble properly using the pMDI,
which can significantly impact the amount of drug deposited. In addition, a large amount
of the aerosolized drug is deposited in the oropharyngeal airway; as a result, less drug is
deposited in the lung. Moreover, the pMDI has fixed drug doses that cannot be changed.
Finally, some patients have negative reactions to the propellant, particularly when using
old chlorofluorocarbon (CFC) pMDIs.
An In Vitro Comparison
In an in vitro model, Rau et al. (2004) compared the performance of five nebulizer
models: two with constant-output (a Misty-Neb and a SideStream), one breath-enhanced
nebulizer (Pari LCD), and two dosimetric nebulizers (Circulaire and AeroEclipse). The
results showed that the inhaled drug percentages were highest with the AeroEclipse
(38.7%) versus with the Misty-Neb (17.2%) and with the SideStream (15.8%). The
percentage of drug lost to the ambient air was highest with the Misty-Neb (26.8%) and
lowest with the AeroEclipse (6.6%). Duration of nebulization was shortest with the
6

Circulaire (7 min) and longest with the AeroEclipse (14.4 min). According to Rau et al.,
nebulizers differ considerably, and the dosimetric AeroEclipse resulted in the largest
inhaled drug deposition and the lowest loss to ambient air.
An In Vivo Comparison
Many in vivo studies compare the clinical efficacy when using a nebulizer versus
using a pMDI+VHC. Wildhalber, et al. (1999) compared lung deposition in 17 stable,
asthmatic children, using a nebulizer and pMDI+VHC. Body and lung deposition of
radiolabeled salbutamol was assessed with a gamma camera after children inhaled the
medication from a nebulizer and a pMDI+VHC. They found that for the same age groups,
there were comparable percentages of total lung deposition of radiolabeled salbutamol
aerosolized using either a nebulizer or a pMDI+VHC. However, they found that the
delivery rate per minute and the total dose of salbutamol deposited were considerably
higher for the nebulizer.
Blake, et al. (1992), in a double-blinded, randomized, crossover design, evaluated
different doses of albuterol administered either by JN or by pMDI. They used histamine
bronchoprovocation as a bioassay for the amount of drug reaching the beta 2 receptors in
the lung. Their results indicated that the higher doses of the nebulizer solution delivered
more drug to the lung than the lower doses from the pMDI. They also estimated that 10
puffs from the pMDI (0.9 mg) would deliver approximately the same amount of albuterol
to lung receptors as 2.5 mg of the nebulizer solution. They concluded that differences in
dose, administration technique, nebulizer system efficiency, and severity of airway

7

obstruction could alter the amount of drug reaching the beta 2 receptors in the lungs and,
thus, the clinical response.
Poole, et al. (2004) conducted a randomized, crossover trial that included 24
COPD patients with severe exacerbation. The authors investigated whether there were
differences in pulmonary function and in the perception of breathlessness when a
bronchodilator was administered via nebulizer or via a pMDI with a spacer. Their
findings showed that the subjects were significantly less breathless after 5 minute of
salbutamol administration by nebulizer; however, after 45 minutes, both treatments
resulted in equivalent relief. Additionally, there was no difference between the two
treatments in terms of forced expiratory volume in one second (FEV1) and vital capacity
(VC). Despite the early improvement during the first 5 minutes of breathlessness after the
JN was used, the authors concluded that these findings were not enough to justify the
frequent or routine use of a JN to treat patients with severe COPD.
Newman, et al. (2002) conducted a large, prospective, nonblinded,
nonrandomized study of adult asthmatic patients to compare the efficacy of albuterol
administered by a pMDI with a spacer versus a nebulizer. They reported that the peak
expiratory flow rate (PEFR) and the arterial oxygen saturation (SaO2) were higher after
the administration of pMDI compared to postnebulization. Moreover, they found a
significant reduction in the time patients spent in the emergency department when a
pMDI was used. Additionally, they observed significant lower relapse rates among
patients who used the pMDI. However, the latter could be the result of researchers’ bias,
8

non-randomization, and the effect of corticosteroid that was given during the phase of the
pMDI.
Clinical Efficacy Conclusion
Cates, et al. (2008) conducted a systematic review to evaluate the effects of VHCs
versus nebulizers for the delivery of beta2-agonists for acute asthma. The study included
27 randomized controlled trials (RCTs) of adults (n=614) and children (n=2295) over
more than two years in the emergency department (ED) and community settings.
Additionally, they reviewed another six trials of adult (n=28) and children (n=28) from
an inpatient setting. They concluded that a pMDI with a spacer produced outcomes that
were at least equivalent to nebulizer delivery. They also stated that pMDIs with spacers
might have some advantages compared to nebulizers for children with acute asthma.
In a meta-analysis, Dolovich, et al. (2005) compared the clinical efficacy of
nebulizers versus pMDIs with and without a spacer/VHC versus a dry powder inhaler
(DPIs) for several clinical settings and patient populations. This meta-analysis covered 59
RCTs between years 1982 and 2001 that primarily tested beta2-agonists. Their results
showed no significant difference between devices in term of efficacy of any patient group
for each of the four clinical settings that were investigated: ED, intensive care unit (ICU),
outpatient, and inpatient.
Castro-Rodriguez, et al. (2004), in another meta-analysis, compared the efficacy
of beta-agonists given by a pMDI with a VHC or a nebulizer to children under 5 years of
age with moderate to severe acute exacerbations of wheezing or asthma in the ED setting.
9

They reviewed six RCTs (n=491) that were published between 1966 and 2003. The
results showed a significant reduction in the admission rate for patients who received
beta-agonists via a pMDI with a VHC compared with those who received them by
nebulizer. Additionally, the pMDI with VHC group showed a significant improvement in
clinical scores compared to those who used a nebulizer.
Cost–Benefit Comparison of JN Versus pMDI With VHC
Based on many of the studies that have been presented in this paper as well as the
high cost of respiratory care services, many hospitals have begun to move to more costeffective methods such as the pMDI to deliver aerosolized medication. In light of this
change, several researchers have compared the two approaches—JN and pMDI with a
VHC—in an attempt to determine whether the use of a pMDI is cost effective.
In an in-patient setting, Jasper, et al. (1987) compared the use of JN administered
by a respiratory therapist (RT) to the self-administered pMDI among 34 COPD patients.
They found that both methods were clinically equivalent. Additionally, they calculated
the cost of such therapy based on their 1985 complete audit of aerosol therapy. They
found the annual cost of JN to be $299,193, which included annual equipment costs
($16,495) and medication and labor costs ($47,038). Also, assuming that all treatments
could be given by inhaler, they calculated the total cost of using a pMDI with a spacer to
be $45,706 per year, which included the cost of instruction, the cost of the spacer, and the
cost the pMDI itself. Making the assumption of possible total replacement, they reported
that the direct cost saving would be around $253,000 annually. This included the
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medication and the labor costs for one year. However, their assumption of the absolute
total replacement of JN is not achievable.
In 1992, Bowton, et al. evaluated the impact of routine substitution of a pMDI for
nebulizer therapy in a 700-bed hospital. Using data from the time-management studies at
their institution, they estimated the therapist’s time spent administering each treatment,
which included initial setup, patient instruction, and follow-up visits. Based on this time
estimate and the therapist’s hourly wage of $13.70, the costs of aerosol delivery were
calculated. In addition, they calculated the equipment and the drug costs (albuterol pMDI
canister cost $7, spacer cost $4.50, JN including daily change cost $1, and unit-dose of
albuterol cost $0.54 per treatment). Total patient charges were calculated to be $13 per
JN treatment, $16.50 for the initial pMDI treatment, and $5 for pMDI treatment followup. After the hospital had achieved an approximately 60% substitution of pMDI for
nebulizer, they reported a significant reduction in the total cost to deliver aerosol therapy,
from $27,600 to $20,618. They stated that their hospital could achieve a potential cost
savings of $83,000 annually.
In 1996, Turner, et al. over a 6 week period, evaluated the cost of aerosol therapy
(with pMDI, nebulization, or both) administered to 95 patients at four preselected
hospital wards. Of these 95 patients, 6.3% received a pMDI, 70.5% received
nebulization, and 23.2% received both. Salbutamol and ipratropium bromide doses,
frequency, and delivery methods—either pMDI or nebulizer—were recorded for the 95
patients treated with aerosolized bronchodilators. The authors determined direct costs for
11

medications and hourly wages including benefits and equipment. They used time and
motion studies to identify time allocated to pMDI and nebulization delivery and
sensitivity analyses to test assumptions that could significantly affect treatment costs,
especially assumptions about medications, labor, and spacer devices. Their results
showed that the delivery of aerosol therapy using a pMDI was the least expensive
method.
Another RCT by Leversha, et al. (2000) compared the cost and effectiveness of
albuterol delivery administered via a pMDI+VHC versus a nebulizer to 60 children with
moderate to severe asthma who presented to the emergency department. They calculated
the cost of the medication, equipment (which included a spacer, masks, and a nebulizer
bowl), the ED presentation, and, for those requiring admission, the cost of the resulting
hospital admission. Their management unit provided cost estimates that included the
fixed costs, human resources, and investigation and treatment costs. Their hospital
benchmark estimates in 1996 (presented in New Zealand Dollar) were NZ$190 (roughly,
US$148.751) for each ED presentation and NZ$1814 for each hospital admission for
asthma. They found that the mean total cost was NZ$825 (roughly, US$645.892) for the
holding chamber group (n=30) and NZ$1282 (roughly, US$1,003.68) for the nebulizer
group.
Dhuper, et al. (2008), in a prospective randomized double-blind study, compared
the efficacy and cost using a pMDI with a spacer and a nebulizer among 60 acute
asthmatic patients who presented to the ED. As previous studies concluded, they found
12

no differences between the two groups in terms of efficacy. Their cost analysis was based
only on treatments with albuterol and did not include placebo administration. Payroll
costs (including fringe benefits) for a respiratory therapist in their institutions was on
average $40.94 per hour. They estimated that it took the therapist approximately 10
minutes to instruct the patient on how to use the pMDI with a spacer, and this had to only
be done once throughout the entire emergency department stay. For the nebulizer group,
each treatment took approximately 12 minutes of the therapist’s time. Thus, the cost for
the respiratory therapist’s time represented the biggest difference in cost between the two
groups, with a constant $6.82 per patient among the pMDI with spacer group and a
median cost of $16.38 for the nebulizer group. There was a one-time cost per patient for
the delivery system of $2.95 for the LiteAire spacer and $1.50 for the nebulizer. More
importantly, the total cost for using the pMDI with a spacer was significantly lower
(median of $10) compared to the nebulizer cost ($18). They concluded that a pMDI with
a spacer could offer an economical alternative to nebulization for aerosol delivery.
Conversions to pMDI Protocols: Success and Failure
While the substitution of a pMDI for nebulizer treatment could save money by
allowing staff time to be reallocated, which would in theory increase productivity, such a
policy needs proper planning and careful implementation. Like any process, pre-planning
for implementation of such a change is the cornerstone of success.
In a pediatric hospital, Salyer, et al. (2008) introduced their approach to switch
from using a nebulizer to using a pMDI with VHC. At the beginning, they formed a team
13

to promote the implementation of this conversion. Their intervention comprised four
parts: a literature review, products selection, policy and operational changes, and staff
training. After the literature review and products selection were completed, they revised
the policy and procedures for the respiratory care department to ensure that pMDI+VHC
was the initial method to be used with patients. Respiratory therapists and nurses were
trained and informed of the conversion. Physicians were notified and the default mode of
delivery was changed to pMDI in their computerized physician order entry system. After
3 months of processing and implementation, their respiratory care department was able to
increase the usage of pMDI+VHC from 25% to 77% among all non-ICU patients, and
from 10% to 79% among patients with asthma only. These results indicate a huge success
while emphasizing that a complete conversion was not expected. They acknowledged that
pMDI is not appropriate for every case.
In the respiratory therapy section, at Cleveland Clinic Foundation, Orens, et al.
(1991) implemented a policy to change from a small volume nebulizer (SVN) to a
pMDI. A general rule was announced that a pMDI should be prescribed whenever
possible. Over two years (1988–1990), they were able to increase pMDI use from 5% to
18%. Obstacles that hindered more widespread conversion included the inability of some
patients to use a pMDI and the unavailability of some medications in a form that could be
used with a pMDI. The authors also touched on another obstacle that hindered further
conversion: Some physicians continued to order the use of a SVN because they were
under ―a persisting misimpression‖ that it was more effective than a pMDI.
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In 1992, Bowton, et al. evaluated the success and effect of the routine conversion
to pMDI in a 700-bed tertiary hospital. Before implementation, they educated the RTs
and medical staff about the perceived benefits of such a conversion. Then, they
implemented a policy that stated that all beta2-agonist nebulization orders were to be
administered via pMDIs. The accepted exceptions to this rule were if a physician ordered
that no substitution take place, if a patient was not cooperative, or if the respiratory
therapist, using his or her judgment, recommended an SVN. They were able to achieve a
conversion of more than 60% to pMDIs. They attributed their success mainly to the
comprehensive educational programs directed at respiratory therapists and physicians that
took place before the substitution was implemented.
Hendeles et al. (2005) reported another conversion experience. Their initial effort
to change to pMDIs for the administration of albuterol, ipratropium bromide, or a
combination of two took place in their surgical ICU for mechanically ventilated patients.
They formed a committee that recommended the change in two phases. In the first phase,
physicians were asked by respiratory therapists to change the orders for each patient to
pMDI+VHC. In the second phase, after acceptance of their policy, the committee
approved a pilot program that allowed automatic conversion in all adult ICUs, whether
they were ventilated or not. Exclusion criteria included the need for continuous
nebulization and the need for more than four doses per hour. Patients were also excluded
from this policy if other drugs such as N-acetylcysteine were mixed with the
bronchodilator or if a physician ordered that no substitution be made. At the end of the 615

month pilot program, conversion was extended throughout the hospital and also began to
encompass children. At the end of the first 6 months, there was a decline in SVN
treatment of around 30% and approximately a 53% increase in pMDI usage. In non-ICU
areas, however, the authors found that none of the patients had been switched, not
because any of the exclusion criteria had been met, but rather because of a lack of
adherence to the policy. They concluded ―a policy to switch patients from SVN to
pMDI+VHC for administration of bronchodilator was met with limited success.‖
(Hendeles, Hatton, Coons, & Carlson, 2005, p. 1060).
Economical Evaluation
Economic evaluation refers to the comparison of alternative courses of action,
such as switching to a pMDI, in terms of their costs and consequences (Douglas &
Normand, 2005). With introduction of new procedures or new drugs, it is crucial to
assess its impact on two axes: the clinical and the economic outcomes. Since clinical
outcomes of conversion to pMDI use have been sufficiently assessed and results have
demonstrated it to be equal to other methods of delivery, it is imperative to evaluate its
impact on cost. A variety of techniques can be used to conduct an economic evaluation.
For example, in a cost-minimization analysis, which is the simplest form of economic
evaluation, the researcher would evaluate the cost differences between two or more
products or procedures that have been deemed by the literature to be equivalent (Douglas
& Normand, 2005). Hence, the purpose of such an evaluation is to determine which
substitute would result in the use of fewer health care resources (and thus would lower
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costs) (Douglas & Normand, 2005). That type of analysis is often confused with costeffectiveness analysis, in which different outcomes of two different interventions are
expected.
Additionally, as Camargo et al. (2000) have shown, there are many types of costs.
The authors categorized costs as either direct or indirect, with direct costs representing
the expenditure for goods or services. Examples of this type of cost include labor,
equipment, and medication. In contrast, indirect costs are other expenses that usually
result from loss of productivity. For example, patients may be unable to work because of
an asthma attack.
Economic evaluation of aerosol therapy must include all related costs. The initial
setup, equipment, medication, and labor must all be considered. Labor, which plays a
major role in reducing the cost when switching from nebulization to pMDI+VHC, must
be assessed very carefully. While many studies have recorded labor as a variable cost
(i.e., based on each treatment) it should really be treated as a fixed cost (Camargo &
Kenney, 2000).This means that labor does not change proportionally with volume change
in the short term. ―Determining the labor cost per minute and multiplying that figure by
the number of minutes expended on a therapy ignores that a hospital’s labor payments are
fixed in the short term‖(Camargo & Kenney, 2000, p. 761).
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CHAPTER III
III.

METHODOLOGY
Bench Model

The bench model consisted of JN, BAN, or pMDI+VHC connected to an air flow
compensated Thorpe flow meter; the pMDI+VHC was attached to the face of an adult teaching
manikin. A mouthpiece was connected to the face of the manikin. Below the bifurcation, an
elbow adaptor was connected to a corrugated tube and was angled to be at a lower level than the
collecting filter to prevent droplets from dripping directly into the collecting filter. From the
collecting filter, another corrugated tube was connected to a prevention filter, which was then
connected to an adult breathing simulator. An adult breathing simulator (Harvard Apparatus
Dual Phase Control Respirator Pump, LSU Medical Center, Shreveport, LA) was used to
simulate adult spontaneous breathing cycles. Tidal volume (VT) was set at 450 ML, the
respiratory rate (RR) at 20 breaths/min, and the inspiratory to expiratory ratio (I:E) was 1:2. VT
was assessed multiple times using the Wright Respirometer (Harris Lake Inc., Cleveland,
OH) and 450 ml was verified with each breath. Figure 1 shows the experimental model with
the three aerosol delivery devices used in this study.
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Figure 1 Experimental Setup with the three aerosol delivery devices used in this study
Efficiency of JN, BAN and pMDI+VHC Using 3 ml or 4 Puffs
This experiment compared three aerosol generators: JN, BAN, and pMDI+VHC.
The two nebulizers were tested using a simulated spontaneous adult breathing pattern.
(1) The Salter Labs 8900 nebulizer (Salter Labs, Arvin, CA) is a constant-output
pneumatic jet nebulizer. (2) The AeroEclipse (Monaghan Medical Corp, Plattsburgh,
NY) is a mechanical breath-actuated nebulizer. First, each nebulizer aerosolized the unitdose of albuterol sulfate solution of 2.5 mg with a 3 mL total fill volume (Nephron
Pharmaceuticals, Orlando, FL). No additional diluents were added to either nebulizer.
Both nebulizers were powered by 50-psi of oxygen at 8 l/min. and operated until the
onset of sputter, with no tapping of the nebulizer, and the time to sputter was recorded
with a stopwatch.
The ProAir Inhaler (Teva Specialty Pharmaceuticals, Horsham, PA) is an HFAbased pMDI that contains albuterol sulfate. The 108-μg ProAir (equivalent to 90 μg
from the mouth piece) was used with the AeroChamber Plus (Monaghan Medical,
Plattsburgh, NY), which is a VHC with antistatic properties. After shaking, the pMDI
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was primed with three actuations, and then pMDI+VHC was actuated four times with a
30-second waiting time between actuations. Each actuation was done in synchrony with
a beginning of the inspiratory phase, and the same investigator actuated the pMDI to
ensure the consistency of medication delivery.
Efficiency of JN, and BAN Using 1 ml
In this experiment, two nebulizers were compared: a JN and a BAN. Salter Labs
8900 nebulizer (Salter Labs, Arvin, CA) is a constant-output pneumatic jet nebulizer. The
AeroEclipse (Monaghan Medical, Plattsburgh, NY) is considered a mechanical breathactuated nebulizer. Each nebulizer aerosolized a concentrated dose of albuterol sulfate
solution (Nephron Pharmaceuticals, Orlando, FL) of 2.5 mg/ 0.5 ml with an additional
volume of 0.5 ml for a total fill volume of 1 ml per nebulizer. Each of the nebulizers
was powered by 50-psi of oxygen at 8 L/min. and operated until the onset of sputter,
with no tapping of the nebulizer, and the time to sputter was recorded with a stopwatch.
Measurement of Drug
Each experiment was repeated three times (n=3) using a simulated spontaneous
adult breathing pattern. In each trial, the total aerosol drug mass was measured based
on the amount of drug deposited in the collecting filter. All drug amounts were
analyzed via spectrophotometry (Beckman Instruments, Fullerton, CA) at a wavelength
of 276 nm. Collecting filters were washed with hydrochloric acid (JT Baker Company,
Phillipsburg, NJ) for one minute with gentle agitation. The spectrophotometer was
calibrated prior to the trials using a holmium oxide filter (Beckman Instruments,
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Fullerton, CA) to determine wavelength accuracy and it was set to zero using the solvent
alone before each analysis.
Data Analysis
Means and standard deviations were calculated for each component of the inhaled
mass percentage, treatment time, and residual volume. In the comparison of JN, BAN, and
pMDI, we used one-way ANOVA to compare the inhaled mass percentage, and treatment
time of the three devices. Multiple follow-up comparisons were performed if the p value
was significant. In addition, we used independent t test to compare the residual volume of
the nebulizer. In the comparison of JN, and BAN (1 ml fill volume), however; independent
t test was used to compare the inhaled mass percentage, treatment time, and residual
volume. Differences were considered statistically significant when p< 0.05. To identify
differences among aerosol generators, all statistical calculations were performed using
commercially available software (SPSS v.18, Chicago, IL).
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CHAPTER IV
I.

RESULTS

Efficiency of JN, BAN and pMDI+VHC Using 3 ml or 4 Puffs
The first experiment, which used 3 ml/ four puffs of albuterol, showed no
statistically significant differences in the inhaled mass percentage among the three
aerosol generators (p=0.172) (Table 1). However, there was a statistically significant
difference among the delivery times (p=0.000). BAN required eight times the
nebulization time of the pMDI. Post hoc analysis showed a significant difference in
treatment time between the BAN and the pMDI (p=0.0001) and between the BAN and
the JN (p=0.0001) but no significant difference between the JN and the pMDI (p=0.196).
Additionally, the BAN and the JN showed no statistically significant difference in
residual volume (p=0.765).
Table 1 Efficiency of Aerosol Generator, JN(Jet Nebulizer),BAN (Breath-Actuated
Nebulizer), and pMDI(pressurized metered dose inhaler ),used in this study.
First Experiment With 3 ml or 4 Puffs

Second Experiment With 1 ml

JN

BAN

pMDI

JN

BAN

Inhaled Mass (%)

15.83± 2.08

23.63± 6.55

18.32 ± 3.53

5.76±1.28

17.25± 3.05

Treatment Time (Min)

2.35 ± 0.18

11.19 ± 0.93

1.42 ± 0.03

0.143 ± 0.05

1.77 ± 0.62

Residual Volume (ml)

1.57 ± 0.55

1.44 ± 0.43

NA

0.86 ± 0.058

0.68 ± 0.145
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Efficiency of JN, and BAN Using 1 ml
The second experiment showed that the BAN was more efficient than the JN
(p=0.004). Additionally, comparisons of delivery time (p=0.010) and residual volume
(p=0.115) showed no statistically significant differences between the JN and the BAN.
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CHAPTER V
II.

DISCUSSION

This study aimed to measure the amount of drug deposited in the lungs by
different aerosol delivery methods. Finding of this study showed no significant difference
in the inhaled mass percentages among JN, BAN, and pMDI when a fill volume of 3 ml
or 4 puffs were used. While BAN delivered more medication than JN with 1 ml, the
residual volume of the BAN was the same as JN. Regardless of the fill volumes used in
this study, the treatment time with BAN was longer than JN and pMDI.
Aerosol Generator Efficiency
First Experiment With A Fill Volume of 3 ml or 4 Puffs
The JN delivered the smallest amount of drug, approximately 16%, which is
comparable to results of previous studies (Rau, et al., 2004). Although the BAN delivered
the highest medication percentage (24%) of the three devices in this study, it was
approximately 15% less than what Rau et al. found in their study (approximately 39%).
One explanation for this big difference may be the models used. In Rau et al.’s
experimental model, they connected the nebulizer directly to a collecting filter and to the
lung simulator, which caused less aerosol particles impaction. The model in this study
was designed to mimic the human anatomy, resulting in greater aerosol particles
impaction and less deposition of drug in the filter. Although the BAN delivered the
highest percentage of medication, it did not reach a statistically significant level.
However, aerosol deposition with BAN using 3 ml is higher than pMDI although it is not
24

statistically significant. What is more important is that the BAN’s delivery time was as
much as five times that of the JN and as much as eight times that of the pMDI. Moreover,
the residual volume with the BAN was comparable to that of the JN with no statistically
significant difference.
Efficiency of JN, and BAN Using 1 ml
This experiment provides crucial and helpful information for practicing
respiratory therapists. The BAN delivered as much as three times the amount of the drug
that the JN delivered and in less than two minutes. In fact, it delivered more than the
amount of drug deposited by the JN when a 3 ml fill volume was used in the first
experiment. Also the BAN with 1 ml delivered nearly the same amount of albuterol as the
pMDI. Surprisingly, the JN reached sputter in about 14 seconds, which reveals the poor
effectiveness of the device. An even more unexpected result was that the JN left a dead
volume of nearly 87% of the original fill volume compared to 67% with BAN.
Limitations
Like any other study, this study has limitations. First, the impact of changing
breathing parameters should be explored to determine how aerosol deposition would be
affected by different patient conditions and diseases. Second, the in vitro lung model used
in this study was not configured to precisely match the human airway, which may have
affected the aerosol deposition and subsequently the results. Because the lung model
collected aerosol prior to the lung (filter at the level of bronchi), we could not determine
aerosol deposition past this point.
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Conclusion
All aerosol devices that were compared using a 3 ml fill volume delivered
comparable inhaled mass percentage with no significant differences. When a 1 ml fill
volume was used, the BAN delivered more drug than the JN. The BAN, however, had the
longest treatment time. When the BAN fill volume was reduced to 1 ml, the pMDI
delivered approximately the same amount of medication as the BAN using a fill volume
of 1 ml. Future studies should explore the impact of the different aerosol delivery device
and treatment on the cost of aerosol therapy.
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